Last reviewed · How we verify
Test formulation D1
At a glance
| Generic name | Test formulation D1 |
|---|---|
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age (PHASE1, PHASE2)
- Bioequivalence Clinical Trial of Recombinant Human Follicle-stimulating Hormone JZB30 (PHASE1)
- Pharmacokinetics Of Celecoxib Test Formulations (PHASE1)
- Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years (PHASE2)
- Relative Bioavailability Trial of Oral Dispersible Praziquantel Tablets in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Test formulation D1 CI brief — competitive landscape report
- Test formulation D1 updates RSS · CI watch RSS
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. portfolio CI